Drug Profile
Research programme: anticancer therapeutics - Hypha Discovery
Alternative Names: HD148; HD148 series/programme - Hypha DiscoveryLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Hypha Discovery
- Class Heterocyclic compounds
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in United Kingdom